Brain scans reveal Cobenfy's dopamine effects in schizophrenia
NCT ID NCT07423546
First seen Feb 27, 2026 · Last updated Jun 08, 2026 · Updated 15 times
Summary
This study will use special brain scans (PET/MRI) to see how the drug Cobenfy changes dopamine activity in people with schizophrenia. Twelve adults who are not currently taking antipsychotics will take Cobenfy for 5 weeks and get scans before and after. The goal is to understand how Cobenfy works in the brain, not to treat symptoms directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA 1 (DISORDER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.